Mifepristone for Early Abortion

Phase-Based Progress Estimates
Early Abortion+1 More
Mifepristone - Drug
Any Age
What conditions do you have?

Study Summary

This trial will test if it's feasible to mail abortion medication to patients, who will then take it at home.

Eligible Conditions
  • Early Abortion
  • Pregnancy Related

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Day 14 following initial medication abortion visit

Day 14
Proportion of patients who report positive experience.
Day 3
Proportion of patients who report timely delivery of medication.
Week 6
Proportion of patients who have a complete abortion

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Side Effects for

13%Drug Rash
This histogram enumerates side effects from a completed 2016 Phase 4 trial (NCT01990560) in the Mifepristone ARM group. Side effects include: Hypokalemia with 13%, Drug Rash with 13%.

Trial Design

1 Treatment Group

Medication Abortion Patients
1 of 1

Experimental Treatment

538 Total Participants · 1 Treatment Group

Primary Treatment: Mifepristone · No Placebo Group · Phase 4

Medication Abortion Patients
Experimental Group · 1 Intervention: Mifepristone · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 14 following initial medication abortion visit

Who is running the clinical trial?

Daniel Grossman, MDLead Sponsor
University of California, San FranciscoLead Sponsor
2,263 Previous Clinical Trials
11,469,551 Total Patients Enrolled
2 Trials studying Early Abortion
3,000 Patients Enrolled for Early Abortion

Eligibility Criteria

Age Any Age · Female Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You may be eligible to receive Mifeprex at a study site
customer service We provide customer service in English and Spanish
You are willing and able to participate in the study, including willing and able to receive medications at home or other preferred address within 3 days of initial medication abortion visit.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: November 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New York100.0%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%